URM1

Across TCGA pan-cancer cohorts, URM1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated URM1 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher URM1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated URM1 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

BLCA, PCPG, and SARC are the cancer types where URM1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.097	0.626	<.001	33	view →
PCPG	OS	Median	All	0.009	0.946	<.001	12	view →
SARC	DFS	Median	All	0.095	0.632	.002	6	view →
LIHC	OS	Median	All	0.258	0.773	.018	3	view →
STAD	OS	Median	IV	1.000	0.299	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

URM1–BLCA (DFS)

Open the BLCA breakdown →